HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS trial, which evaluated ibrutinib, a Bruton’s tyrosine kinase inhibitor, combined with bendamustine and rituximab (BR) versus vs BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma.